96 related articles for article (PubMed ID: 26770398)
1. The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma.
Zhang Z; Zhang Y; Lv J; Wang J
Int J Clin Exp Med; 2015; 8(10):18032-40. PubMed ID: 26770398
[TBL] [Abstract][Full Text] [Related]
2. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
3. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
[TBL] [Abstract][Full Text] [Related]
4. YM155 exerts a growth inhibitory effect on human osteosarcoma in vitro and in vivo.
Zhang Z; Ma L; Wang J
Oncol Rep; 2015 Aug; 34(2):1074-80. PubMed ID: 26081496
[TBL] [Abstract][Full Text] [Related]
5. Stathmin is key in reversion of doxorubicin resistance by arsenic trioxide in osteosarcoma cells.
Feng T; Qiao G; Feng L; Qi W; Huang Y; Yao Y; Shen Z
Mol Med Rep; 2014 Dec; 10(6):2985-92. PubMed ID: 25310700
[TBL] [Abstract][Full Text] [Related]
6. miRNA‑218 targets multiple oncogenes and is a therapeutic target for osteosarcoma.
Sato K; Osaka E; Fujiwara K; Fujii R; Takayama T; Tokuhashi Y; Nakanishi K
Oncol Rep; 2022 May; 47(5):. PubMed ID: 35293593
[TBL] [Abstract][Full Text] [Related]
7. ABCB1-overexpressing MG63/DOX cell xenograft model: maintain the MDR phenotype in vivo.
Zhou Z; Wan L; Han Y; Meng X; Yang Q; Li Y; Yu Q; Shen Z; Guo C
Pharm Biol; 2013 Aug; 51(8):968-73. PubMed ID: 23735077
[TBL] [Abstract][Full Text] [Related]
8. Alopecurone B reverses doxorubicin-resistant human osteosarcoma cell line by inhibiting P-glycoprotein and NF-kappa B signaling.
Xia YZ; Ni K; Guo C; Zhang C; Geng YD; Wang ZD; Yang L; Kong LY
Phytomedicine; 2015 Mar; 22(3):344-51. PubMed ID: 25837271
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Cheng M; Cai W; Huang W; Chen Y; Wu Z; Luo P; Yan W
Eur J Pharmacol; 2018 Dec; 840():1-8. PubMed ID: 30273544
[TBL] [Abstract][Full Text] [Related]
10. Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA.
Zhao J; Mu X; Hou X; Zhang X; Li P; Jiang J
Front Oncol; 2023; 13():1111855. PubMed ID: 36756155
[TBL] [Abstract][Full Text] [Related]
11. Codelivery of survivin inhibitor and chemotherapeutics by tumor-derived microparticles to reverse multidrug resistance in osteosarcoma.
Wei D; Li C; Ye J; Xiang F; Xu Y; Liu J
Cell Biol Int; 2021 Feb; 45(2):382-393. PubMed ID: 33135822
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
Higuchi T; Sugisawa N; Miyake K; Oshiro H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Kline Z; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Biomed Pharmacother; 2019 Oct; 118():109356. PubMed ID: 31545293
[TBL] [Abstract][Full Text] [Related]
13. YM155 exerts potent cytotoxic activity against quiescent (G
Ookura M; Fujii T; Yagi H; Ogawa T; Kishi S; Hosono N; Shigemi H; Yamauchi T; Ueda T; Yoshida A
Oncotarget; 2017 Dec; 8(67):111535-111550. PubMed ID: 29340073
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.
Nestal de Moraes G; Vasconcelos FC; Delbue D; Mognol GP; Sternberg C; Viola JP; Maia RC
Eur J Cell Biol; 2013; 92(8-9):247-56. PubMed ID: 24064045
[TBL] [Abstract][Full Text] [Related]
15. Surviving Inhibition Induces Cell Cycle Arrest and Disrupts Multipotency in Haemangioma Stem Cells.
Wang BK; Li HM; Yang JG; Ren JG; Cai Y; Zhao JH; Zhao YF; Jia J; Zhang W
Chin J Dent Res; 2021 Apr; 24(1):21-31. PubMed ID: 33890452
[TBL] [Abstract][Full Text] [Related]
16. m
Zhang D; Guo Q; You K; Zhang Y; Zheng Y; Wei T
J Orthop Surg Res; 2024 Jan; 19(1):33. PubMed ID: 38178201
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
Cao Y; Huang HY; Chen LQ; Du HH; Cui JH; Zhang LW; Lee BJ; Cao QR
ACS Appl Mater Interfaces; 2019 Mar; 11(10):9763-9776. PubMed ID: 30776886
[TBL] [Abstract][Full Text] [Related]
18. Geniposide reverses multidrug resistance
Huang H; Zhang X; Huang Z; Zhang Y; Zhou Z
Exp Ther Med; 2017 Feb; 13(2):437-442. PubMed ID: 28352312
[TBL] [Abstract][Full Text] [Related]
19. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
Wang Z; Liu Z; Wu S
Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
